\

Cancer Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Gary Kelloff, M.D., NIH/NCI, (Co-Chair)

Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair)

Alex Snyder, Ph.D., Generate Biomedicines (SITC) (Co-Chair)

Alexandre Akoulitchev, Ph.D., Oxford Biodynamics

Jeff Allen, Ph.D., Friends of Cancer Research

J. Carl Barrett, Ph.D., University of North Carolina

Anna Berdine, M.S., Alamar Biosciences, Inc.

Michelle Berny-Lang, Ph.D., NCI

Donald A. Berry, Ph.D., MD Anderson Cancer Center

Vikram Bhadrasain, M.D., NCI

Gary Borzillo, Ph.D., Janssen

Trixia Camacho, PharmD, BMS

Claudio Carini, Ph.D., Kings College London

Ronald Cheung, Jazz Pharmaceuticals

Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation

Steven Cole, NCI

Cecile Combeau, Ph.D., Sanofi

Adam Corner, BioRad

Ed Driggers, Ph.D., General Metabolics

Michael Espey, Ph.D., NCI

Fennessy, Fiona M., PhD, MBBCH, RSNA

Ida Grundberg, Ph.D., Olink

Justin Guinney, Ph.D., Tempus

Stanley R. Hamilton, M.D., City of Hope National Medical Center

Sean Hanlon, Ph.D., NCI

Lyndsay Harris, M.D., NCI

Stephanie Hennek, Ph.D., PathAI

Brandon Higgs, Ph.D., Genmab US, Inc.

Steffan Ho, M.D., Ph.D., Pfizer

Rob Iannone, M.D., Jazz Pharmaceuticals

Peter Intile, SITC

Donald Jackson, Ph.D., Sanofi

Taylor Jensen, Ph.D., LabCorp

John Jessup, M.D., Institute for Bioscience and Biotechnology Research

Morten Karsdal, Ph.D., Nordic Bioscience

Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies

Jessica Kuzma, Ph.D., Standard Biotools

Laura Lasiter. Ph.D., AstraZeneca

Robert McCormack, Ph.D.,Janssen

Doug Mirsky, Ph.D., Digital Medicine Society

Achim Moesta, Ph.D., Regeneron

Andrea Mortera, Empatica

Veerendra Munugalavadla, Ph.D., AstraZeneca

Larry Nagahara, Ph.D., John’s Hopkins University

Michael O’Neal, M.D., Clario

Geoff Oxnard, M.D., Eli Lily & Company

Snehal Patel, Ph.D., Association for Molecular Pathology

Reena Philip, Ph.D., FDA/OCE

Vladimir Popov, Ph.D., FNLCR/NCI

Scott Knowles Pruitt, M.D., Ph.D., Merck

Anita Reddy, Ph.D., Amgen

Michael Reeder, Ph.D., Johnson & Johnson

Henry Rodriguez, Ph.D., NIH/NCI

Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company

Marijana Rucevic, Ph.D., Olink Proteomics

Mert Sahin, Ph.D., Durin Technologies

Lawrence Schwartz, M.D., Memorial Sloan Kettering

Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research

Howard Spiegel, Olink Proteomic

Funda Suer, Ph.D., Durin Life Sciences

Magadelena Thurin, Ph.D., NIH/NCI

Peter Ujhazy, M.D., Ph.D., NIH/NCI

Tamar Uziel, Ph.D., AbbVie

Sarah Valentine, Digital Medicine Society

Megann Vaughn, M.B.A., LabCorp

Jian Wang, Ph.D., AstraZeneca

Joel Wommack, Ph.D., Standard Biotools

Rebekah Zinn, Ph.D., FDA